How do patients who fail first-line tb treatment but who are not placed on an mdr-tb regimen fare in south india?

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Nagaraja, Sharath Burugina ^a   Satyanarayana, Srinath ^b   Chadha, Sarabjit Singh ^b   Kalemane, Santosha ^c   Jaju, Jyoti ^a   Achanta, Shanta ^a   Reddy, Kishore ^d   Potharaju, Vishnu ^d   Shamrao, Srinivas Rao Motta ^e   Dewan, Puneet ^a   Rony, Zachariah ^f   Tetali, Shailaja ^g   Anchala, Raghupathi ^g   Kannuri, Nanda Kishore ^g   Harries, Anthony David ^b,i   Singh, Sachdeva Kuldeep ^h  

^a Office of the WHO Representative in India   (India)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c Impact Health Solutions   (India)

^d State Tuberculosis Training and Demonstration Centre   (India)

^e Directorate of Health Services   (India)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^h GOVERNMENT OF INDIA   (India)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CHILD; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; RETREATMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; SPUTUM SMEAR; TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; TREATMENT FAILURE;

MYCOBACTERIUM;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 80053961954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025698     Document Type: Article

References (10)

1. Central Tuberculosis Division (2010) Tuberculosis India 2010. Annual Report of the Revised National Tuberculosis Control Programme. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
2. Central Tuberculosis Division (2005) Technical and Operational Guidelines for Tuberculosis Control, Revised National Tuberculosis Control Programme. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
3. Central Tuberculosis Division (2010) DOTS Plus Guidelines, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
4. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283: 2537-2545 joc92107 [pii].
5. Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, et al. (2009) Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One 4: e7954 10.1371/journal.pone.0007954 [doi].
6. World Health Organisation, Geneva (2010) Treatment of Tuberculosis: Guidelines-4th edition.
7. Central TB Division (2006) Procurement Manual of the Revised National Tuberculosis Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
8. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005-1015 10.1056/NEJMoa0907847 [doi].
9. World Health Organisation, Geneva (2003) Treatment of Tuberculosis. Guidelines for National Programmes. 3rd Edition.
10. von EE, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370: 1453-1457 S0140-6736(07)61602-X [pii];10.1016/S0140-6736(07)61602-X [doi].